Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Deyuan Pharmaceutical Co Scaled Net Operating Assets Chart
BJSE:920735 vs ZTS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Deyuan Pharmaceutical Co Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.54 mean?
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) has a Scaled Net Operating Assets of 0.54 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors.
Is Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets too high?
Jiangsu Deyuan Pharmaceutical Co's current Scaled Net Operating Assets is 0.54. Overall, Jiangsu Deyuan Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets compare to ZTS?
Jiangsu Deyuan Pharmaceutical Co's Scaled Net Operating Assets of 0.54 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors. Jiangsu Deyuan Pharmaceutical Co's current Scaled Net Operating Assets is 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Deyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.61, compared to a current price of ¥26.66 — trading 10% below its estimated fair value. The current Scaled Net Operating Assets is 0.54. Jiangsu Deyuan Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Jiangsu Deyuan Pharmaceutical Co (BJSE:920735), the current Scaled Net Operating Assets is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥26.66 is trading 10% below its estimated GF Value™ of ¥29.61.
GuruFocus considers Jiangsu Deyuan Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920735:
Scaled Net Operating Assets: 0.54
GF Value™: ¥29.61 vs. price of ¥26.66 (10% below fair value)
No single metric tells the full story. See the BJSE:920735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920735 has been successfully added to your 
